2022 Insights on Cough, Cold and Allergy (Hay Fever) Remedies in the United States: Growth for Cough and Cold Medications Due to the Rise of Respiratory Illnesses – ResearchAndMarkets.com
2022 Insights on Cough, Cold and Allergy (Hay Fever) Remedies in the United States: Growth for Cough and Cold Medications Due to the Rise of Respiratory Illnesses – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Cough, Cold and Allergy (Hay Fever) Remedies in the US” report has been added to ResearchAndMarkets.com’s offering.
Over a year since FDA approval to switch to the OTC market, allergy nasal spray Astepro is now available at retail locations. Astepro is the first and only 24-hour over-the-counter antihistamine nasal spray that is steroid-free.
The 0.15% strength of its active ingredient, azelastine, was the only formulation to be approved for the treatment of rhinitis, and its 0.1% strength formulation for children younger than six remains a prescription product.
The Cough, Cold and Allergy (Hay Fever) Remedies in USA report offers a comprehensive guide to the size and shape of the market at a national level. It provides the latest retail sales data 2017-2021, allowing you to identify the sectors driving growth. Forecasts to 2026 illustrate how the market is set to change.
Product coverage: Antihistamines/Allergy Remedies (Systemic), Combination – Cough, Cold and Allergy (Hay Fever) Remedies, Cough Remedies, Decongestants, Medicated Confectionery, Paediatric Cough, Cold and Allergy Remedies, Pharyngeal Preparations.
Data coverage: Market sizes (historic and forecasts), company shares, brand shares and distribution data.
Why buy this report?
- Get a detailed picture of the Cough, Cold and Allergy (Hay Fever) Remedies market;
- Pinpoint growth sectors and identify factors driving change;
- Understand the competitive environment, the market’s major players and leading brands;
- Use five-year forecasts to assess how the market is predicted to develop.
Key Topics Covered:
COUGH, COLD AND ALLERGY (HAY FEVER) REMEDIES IN THE US
KEY DATA FINDINGS
2022 DEVELOPMENTS
- Bayer’s Astepro hits the US market following its successful Rx-to-OTC switch
- Growth for cough and cold medications due to the rise of respiratory illnesses
- Still wary about COVID-19, some consumers are eager to pre-emptively treat symptoms
PROSPECTS AND OPPORTUNITIES
- Potential for longer flu seasons could create greater opportunity for year-round sales
- Antihistamines/allergy remedies set to perform well over the forecast period
- Herbal/natural trend set to expand, especially for paediatric products
CATEGORY DATA
- Table 1 Sales of Cough, Cold and Allergy (Hay Fever) Remedies by Category: Value 2017-2022
- Table 2 Sales of Cough, Cold and Allergy (Hay Fever) Remedies by Category: % Value Growth 2017-2022
- Table 3 NBO Company Shares of Cough, Cold and Allergy (Hay Fever) Remedies: % Value 2018-2022
- Table 4 LBN Brand Shares of Cough, Cold and Allergy (Hay Fever) Remedies: % Value 2019-2022
- Table 5 Forecast Sales of Cough, Cold and Allergy (Hay Fever) Remedies by Category: Value 2022-2027
- Table 6 Forecast Sales of Cough, Cold and Allergy (Hay Fever) Remedies by Category: % Value Growth 2022-2027
CONSUMER HEALTH IN THE US
EXECUTIVE SUMMARY
- Consumer health in 2022: The big picture
- 2022 key trends
- Competitive landscape
- Retailing developments
- What next for consumer health?
MARKET INDICATORS
- Table 7 Consumer Expenditure on Health Goods and Medical Services: Value 2017-2022
- Table 8 Life Expectancy at Birth 2017-2022
MARKET DATA
- Table 9 Sales of Consumer Health by Category: Value 2017-2022
- Table 10 Sales of Consumer Health by Category: % Value Growth 2017-2022
- Table 11 NBO Company Shares of Consumer Health: % Value 2018-2022
- Table 12 LBN Brand Shares of Consumer Health: % Value 2019-2022
- Table 13 Penetration of Private Label in Consumer Health by Category: % Value 2017-2022
- Table 14 Distribution of Consumer Health by Format: % Value 2017-2022
- Table 15 Distribution of Consumer Health by Format and Category: % Value 2022
- Table 16 Forecast Sales of Consumer Health by Category: Value 2022-2027
- Table 17 Forecast Sales of Consumer Health by Category: % Value Growth 2022-2027
APPENDIX
- OTC registration and classification
- Vitamins and dietary supplements registration and classification
- Self-medication/self-care and preventive medicine
- Switches
- Summary 1 OTC: Switches 2021-2022
DISCLAIMER
DEFINITIONS
SOURCES
For more information about this report visit https://www.researchandmarkets.com/r/fkdcok
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900